Front-Line Hyper-CVAD–Based Regimens, Including Hyper-CVAD Plus Ponatinib, in Patients With ALL
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Leukemia Research